| Description |
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1R/5R=389/630 μM) and III receptors (IC50: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects[1][2].
|
| Related Catalog |
|
| In Vitro |
DCG-IV is also an NMDA receptor agonist in the rat cortical slice[3].
|
| In Vivo |
DCG-IV (1-10 mg/kg; i.p.) depresses the phencyclidine (PCP)-induced hyperlocomotion[4]. Animal Model: Male ICR mice weighing about 40 g (PCP-induced locomotor activity)[4] Dosage: 10, 5, or 1 mg/kg Administration: I.p. Result: Reduced spontaneous activities of the animals at 10 or 5 mg/kg.
|
| References |
[1]. Brabet I, et al. Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all clonedmetabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37(8):1043-51. [2]. Bertrand HO, et al. Common and selective molecular determinants involved in metabotopic glutamate receptoragonist activity. J Med Chem. 2002 Jul 18;45(15):3171-83. [3]. Uyama Y, et al. DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice. Brain Res. 1997 Mar 28;752(1-2):327-30. [4]. Tomita N, et al. The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice. Ann N Y Acad Sci. 2000 Sep;914:284-91.
|
